Trials advance subcutaneous plasma therapy for AAT deficiency
Grifols has finished recruiting the second cohort of its Phase I/II study evaluating two different doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% (Alpha-1 15%) as a subcutaneous (SC) option for the treatment of alpha1-antitrypsin (AAT) deficiency.
Cohort 2 patients will receive a 180mg/kg dose of SC Alpha-1 15%, after treatment of cohort 1 patients with 72mg/kg of SC Alpha-1 15% showed a good safety profile.
AAT deficiency is an underdiagnosed genetic disorder that occurs when a patient has low levels of AAT, a protective protein that safeguards the lungs.
“We are excited about the possibility of providing alpha-1 patients with a subcutaneous alternative, giving them more freedom when managing their AAT condition,” said Dr Jörg Schüttrumpf, Grifols Chief Scientific Innovation Officer. “Our commitment to the Alpha-1 community remains unwavering and we continue applying our expertise in plasma science and plasma proteins to innovate new treatment options for patients.”
Augmentation therapy with IV AAT is the standard medical treatment option for patients with severe AAT deficiency and emphysema. A SC option could provide AAT patients the ability to independently administer their treatments from home, enabling greater convenience and flexibility.
“The Alpha-1 Foundation applauds Grifols for their continued commitment to the Alpha-1 patient community,” said Scott Santarella, President & CEO, Alpha-1 Foundation. “Their dedication to providing patients with innovative new treatment options could provide them with flexibility and convenience in managing their weekly vital treatments for AATD. Our thanks to Grifols for this outstanding investment. It is crucial for our community to have continued access to this lifesaving plasma therapy.”
Diana Spencer, Senior Digital Content Editor, DDW
